Latest News and Press Releases
Want to stay updated on the latest news?
-
DURHAM, N.C., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized...
-
Event to be held at NASDAQ MarketSite in New York City from 8:00-11:00 a.m. Eastern Time. Immunology and kidney cancer experts to review the company’s individualized immunotherapies based on the...
-
DURHAM, N.C., Oct. 14, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized...
-
DURHAM, N.C., Oct. 03, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of truly individualized...
-
DURHAM, N.C., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of truly...
-
- Independent Data Monitoring Committee Recommended Continuation of Phase 3 ADAPT Trial of AGS-003 in Metastatic Renal Cell Carcinoma - - Closed on $29.8 million Second Tranche of March 2016...
-
DURHAM, N.C., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of truly individualized...
-
DURHAM, N.C., July 28, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized...
-
DURHAM, N.C., July 27, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized...
-
The investigator-initiated Phase 2 trial is designed to evaluate the virologic impact of the combination of the latency-reversing drug, vorinostat, and AGS-004, the company’s investigational...